The group is sponsoring the event, which will attract physicians from across the globe with an interest in longevity and anti-aging medicine
MIAMI LAKES, Florida— The Global Stem Cells Group (GSCG) is set to sponsor the XI Congreso Mundial de Medicina Antienvejecimiento y Longevidad (World Conference of Anti-Aging and Longevity Medicine) to be held in Mexico City, Mexico on February 16-18, 2020.
The medical congress is expected to attract over 450 physicians and researchers from across the world interested in anti-aging and longevity practices and medical innovations. Over 30 speakers are slated to share information with attendees on a wide range of topics on how to lead a long, healthy life and improve longevity.
The GSCG is set to share a number of its latest innovations with congress attendees, including its newly released GCell technology device. This cutting-edge tool utilizes micrograft technology to harness the natural and powerful restorative capabilities of adipose tissues. Because it is FDA compliant, the device allows physicians across the globe to continue practicing adult stem cells-based procedures.
Additional benefits of GCell technology include shorter treatment times, delivering in-office treatments in around 30 minutes with local anesthesia, as well as less fat collection compared to existing treatments (15 mL versus 50 mL). GCell technology holds exciting implications across a range of medical specialties, including orthopedics, dermatology, cosmetic gynecology, aesthetics, and hair loss.
In addition to its GCell technology, the GSCG will also feature its newest line of stem cells products derived from first-tissue exosomes. Cellgenic Flow Exosomes utilizes the latest science and research available in cellular therapies to deliver a non-surgical approach to creating regenerative responses in a broad range of treatments. The product utilizes exosomes, which replicate the signals given out by stem cells, versus actual stem cells. Exosomes play a pivotal role in cell-to-cell communication and are involved in a wide range of physiological processes. These particles transfer critical bioactive molecules such as proteins, mRNA, and miRNA between cells and regulate gene expression in recipient cells.
“The XI Congreso Mundial de Medicina Antienvejecimiento y Longevidad is one of the world’s premier events connecting physicians and researchers with today’s most innovative treatments and technologies utilizing regenerative medicine,” said Benito Novas, CEO of the GSCG. “As a worldwide leader in training, education, and innovative products in the field of regenerative medicine, the GSCG is pleased to sponsor this congress and share its exciting new portfolio of products with physicians from across the world.”
To learn more about the Global Stem Cells Group and all of the group’s latest news and innovations, visit http://www.stemcellsgroup.com/
The group is set to sponsor the 2nd Congress of Aesthetic Medicine and Regenerative Gynecology to be held in Paraguay
MIAMI LAKES, Florida—The Global Stem Cells Group (GSCG) has announced its sponsorship of the 2nd Congress of Aesthetic Medicine and Regenerative Gynecology to be held on March 12-13, 2020 in Asuncion, Paraguay. The GSCG’s CEO Benito Novas and Development and Research Director Dra. Maritza Novas will each deliver key lectures during the annual medical congress, which will focus on advancements in the fields of aesthetic medicine and regenerative gynecology.
Benito Novas serves as the GSCG’s CEO and will lead a lecture on regenerative medicine marketing strategies. His talk will give practical marketing tools and advice to physicians running their own private practices in aesthetic medicine. In addition to his role as CEO with the GSCG, Novas also serves as the Head of Public Relations for the International Society for Stem Cell Application (ISSCA) and has authored two books on marketing strategies for clinics in the regenerative medicine industry, Your Aesthetic Practice: What Your Patients Are Saying and Marketing Digital en Su Clínica Estética (https://www.thriftbooks.com/a/benito-novas/2752773/).
Dra. Maritza Novas serves as the GSCG’s Development and Research Director as well as the US Director for the ISSCA. She will deliver the opening lecture for the congress, discussing clinical applications of regenerative medicine in the aesthetic field. Her lecture will be informed by clinical case studies demonstrating the efficacy of regenerative treatments in aesthetics. Dra. Novas is well-renowned in the field of regenerative medicine for making a profound impact on her patients through innovative treatment protocols. She has additionally trained countless doctors looking to add regenerative medicine to their practices.
On March 14, following the conclusion of the congress, representatives from the GSCG will also offer a certification course in cellular therapy. The course is designed to help all physicians who want to add stem cells therapies based on birth tissue derived components to their practices. Attendees will learn about the latest stem cell products, such as exosomes, cord blood, and amniotic fluid. Additional topics to be covered will include how to choose the right products to treat specific conditions and details about how to handle the manufacturing process, from selecting a healthy donor through quality control and storage at the medical office.
“The Global Stem Cells Group is pleased to serve as a sponsor for the 2nd Congress of Aesthetic Medicine and Regenerative Gynecology,” said Benito Novas. “We look forward to sharing today’s best research on marketing strategies to help regenerative medicine practices grow their success and influence as well as sharing clinical applications of stem cells treatments in aesthetic medicine. As a global leader in stem cells education, we always look forward to these events to help more physicians gain the knowledge and skills necessary to bring life-saving treatments to more patients across the globe.”
To learn more about the Global Stem Cells Group and all of the group’s latest news and innovations, visit http://www.stemcellsgroup.com/.
The agreement between Global and CHU Mohammed VI in Marrakech will help enhance staff preparation and clinical offerings in regenerative medicine
MIAMI LAKES, Florida— Stem Cells Training Inc., a subsidiary of the Global Stem Cells Group (GSCG), has announced that it has signed an onsite training agreement with Centre Hospitalo-Universitaire Mohammed VI Marrakech (CHU). GSCG faculty will travel to Marrakech, Morocco to provide this invaluable two-day training to CHU’s staff on February 14 and 15, 2020.
The agreement names the GSCG as CHU’s provider of training for the facility’s regenerative medicine staff. Through the deal, the GSCG will provide preparation and education in the latest regenerative medicine techniques and stem cells protocols, focusing on those utilizing adult stem cells and birth tissue derived from stem cells. In addition to on-site training, the agreement also names the GSCG as CHU’s provider for all necessary equipment to implement regenerative medicine treatments.
The additional training and supplies offered through the agreement will allow CHU to incorporate the industry’s most effective stem cells protocols into the hospital’s treatment options.
The Centre Hospitalo-Universitaire Mohammed VI is a regional leader in quality patient care, student education, physician training, and innovative medical research. Located in Marrakech, CHU provides the bustling city with short-, medium-, and long-range care solutions. Counted among its innovative institutional projects, CHU’s Culture and Health program is committed to making the hospital a more human environment for patients seeking care.
“The agreement between the Global Stem Cells Group and the Centre Hospitalo-Universitaire Mohammed VI Marrakech is an important one for both partners,” said Benito Novas, CEO of the Global Stem Cells Group. “As a university institution, CHU is interested in leading clinical trials to prove the safety and efficacy of regenerative medicine treatment protocols—something the GSCG has a vested interest in. This agreement will allow us to train hospital staff to offer cutting-edge treatments to patients in Morocco while helping stem cells treatments gain more traction globally, making them more viable options for physicians to incorporate into their practices.”
With the newly signed agreement, the GSCG continues to advance its mission to expand its presence across the global, especially focusing on North America and the Middle East. Physicians looking to grow their practices by offering regenerative medicine treatments can benefit from the GSCG’s trainings, which are conveniently held onsite at physicians’ home facilities, no matter where they are located globally.
To learn more about the onsite training opportunities offered by the Global Stem Cells Group, visit https://www.stemcelltraining.net/onsitetraining/. To learn more about the Centre Hospitalo-Universitaire Mohammed VI Marrakech, visit www.chumarrakech.ma.
The group will host six events across the globe, combining networking and education for practitioners of regenerative medicine
MIAMI LAKES, Florida— The International Society for Stem Cell Application (ISSCA), a worldwide leader in regenerative medicine education, has announced its slate of 2020 medical congresses. The group’s calendar includes dates at six locations across the globe
Through its congresses, the ISSCA seeks to create a platform through which physicians can collaborate, share data, initiate discussions, and exchange information that may be directly translated to therapeutic applications. All doctors who want to share their medical research are welcome to attend, and the ISSCA welcomes abstract submissions and reviews them on a continuing basis.
For the second year straight, the main topic discussed at ISSCA’s congresses will be how cellular products derived from birth tissue (allogeneic compounds) have revolutionized the industry by delivering safer, shorter stem cells procedures for practitioners. During each event, lecturers will respond to concerns attendees have about how regenerative medicine advances will satisfy FDA regulations and how new technologies could continue to help patients under new FDA laws.
This year, the ISSCA welcomes three new cities to its agenda—Salvador de Bahia, Brazil; Punta del Este, Uruguay; and Jakarta, Indonesia. The six congresses are as follows:
- May 2020: Mexico City, Mexico
- June 2020: Caracas, Venezuela
- August 2020: Salvador de Bahia, Brazil
- October 2020: Buenos Aires, Argentina
- November 2020: Jakarta, Indonesia
- December 2020: Punta del Este, Uruguay
“We at the ISSCA are looking forward to this year’s calendar of congresses, which will provide invaluable networking and educational opportunities to physicians looking to expand their knowledge on current innovations and best practices concerning regenerative medicine,” noted Benito Novas, ISSCA VP of Public Relations. “Our global congresses expand on ISSCA’s mission to continue to serve as the premier educational resource for physicians across the globe looking to introduce stem cells treatments into their practices.”
To learn more about the ISSCA or to register for an upcoming congress, visit www.issca.us.
Adimarket Named as Distributor for Innovative GCell Micrograft Technology
The partnership between Adimarket and Global Medical Group delivers an FDA-compliant stem cells procedure to physicians practicing regenerative medicine across the globe
MIAMI LAKES, Florida—Adimarket, LLC, a subsidiary of the Global Stem Cells Group (GSCG), has entered an agreement with Global Medical Group (GMG) to distribute the brand’s newest product featuring GCell technology. It will be available for purchase to regenerative medicine practitioners via Adimarket’s online store.
Global Medical Group recently announced the launch of their GCell micrograft technology, an autologous tissue suspension that boasts minimal manipulation. The product has application implications for a wide range of medical uses, including orthopedics, dermatology, cosmetic gynecology, aesthetics, and hair loss.
GCell technology would allow regenerative medicine practitioners to continue practicing their adult stem cells-based procedures, as the product meets FDA compliance standards. GMG’s innovative product uses micrograft technology and is a closed system medical device that harnesses the natural and powerful restorative capabilities of adipose tissue. Because the procedure can be performed without using enzymes, GCell technology maintains FDA compliance.
The GCell SVF (Stromal Vascular Fraction) procedure can be performed in-office in around 30 minutes, while previous procedures could take up to two hours. It also utilizes only local anesthesia, and performing physicians only have to collect 15 ml of fat instead of the 50 ml required for traditional protocols.
GCell technology may hold exciting applications for clients looking for treatment options for wound care, hair loss, orthopedic conditions, or aesthetic concerns.
“We are pleased to partner with the Global Medical Group to offer their cutting edge GCell technology in Adimarket’s product portfolio,” said Benito Novas, CEO of the Global Stem Cells Group. “There is a possibility that this innovative technology could lead to incredible advances in various treatment protocols, including those related to wound care, hair loss, orthopedic injuries, or aesthetics. And because it is FDA compliant, GCell technology will be a highly attractive option to regenerative medicine practitioners in the US and abroad.”
The first unit will be launched in the US market next month. Physicians looking to incorporate GCell technology into their practices will be able to find it at www.adimarket.net.
Global Stem Cells Group Releases New Product to Meet Growing Demand for Birth Tissue Derived Compounds
Cellgenic Flow Exosomes has a wide range of therapeutic implications, including hair loss and pain management
MIAMI LAKES, Florida—The Global Stem Cells Group (GSCG) has announced the release of a new product in response to growing demands from regenerative medicine practitioners for cellular products derived from birth tissue. The product, Cellgenic Flow Exosomes, is 100% natural and is available in a 1 mL vial comprised of 5 billion exosomes per mL and is currently manufactured in Mexico and in Global’s US-based facilities.
As the popularity and efficacy of stem cells treatments increase across the globe, the demand for cellular products like Cellgenic have also increased. With this demand in mind, the GSCG–a global leader in stem cell research, patient application, and physician training–sought to create an innovative cellular product to meet the needs of physicians looking to offer regenerative medicine treatments in their existing practices.
Cellgenic is primarily comprised of exosomes, cell-derived non-particles that play a pivotal role in cell-to-cell communication that are involved in a wide range of physiological processes. Exosomes play an important role in the transfer of proteins, mRNA, miRNA, and other bioactive molecules between cells and regulate gene expression in recipient cells, thus influencing various molecular pathways.
An increasing amount of attention has been paid to exosomes in recent years thanks to the wide range of therapeutic implications they may hold. Some of the most effective uses for exosomes have come in hair therapy and pain management.
Using Cellgenic as a treatment for hair loss has resulted in prominent hair growth results in both men and women. It is highly recommended for those who are too young for hair transplant surgery and for those within the earlier stages of the hair loss cycle.
In terms of pain management, Cellgenic has shown promise in delivering relief from pain and discomfort and may potentially stimulate repair as opposed to blocking or masking them. Common pain and degenerative conditions that Cellgenic may help treat include osteoarthritis, knee pain, shoulder pain, nerve pain, tendonitis, and slow- and non-healing wounds and burns.
For doctors who are interested in learning more about Cellgenic, the GSCG has developed an online course to provide them with the relevant knowledge needed to make a decision about incorporating allogeneic compounds into their treatment protocols.
“Global’s newest product innovation, Cellgenic Flow Exosomes, is an exciting addition to our product portfolio,” said Benito Novas, CEO of the Global Stem Cells Group. “Our goal is to continually innovate and meet the demands of physicians practicing regenerative medicine by providing cutting-edge therapies for those suffering from degenerative diseases. The release of our Cellgenic product accomplishes this goal while also contributing to our mission of being a leader in stem cells research.”
To learn more about Cellgenic Flow Exosomes, visit https://cellgenic.com/.
With video lectures and additional tools from some of the most respected names in today’s stem cells field, the course arms practitioners with the necessary knowledge and resources to offer innovative regenerative medicine treatments in their existing practices
MIAMI LAKES, Florida— The International Society for Stem Cell Application (ISSCA) (www.issca.us) has announced it has launched a new online stem cells course, Cellular Therapy. The course adds to the group’s already existing robust offering of onsite and online courses designed to give physicians looking to incorporate regenerative medicine protocols into their practices the education and tools necessary to do so.
Regenerative medicine has been increasingly gaining attention in today’s fast-paced medical world. As more researchers and physicians become interested in studying the field and introducing treatment protocols into their practices, it can be difficult to know which products and practices yield the best results for patients seeking these treatments for relief from degenerative diseases, noted Benito Novas, ISSCA VP of Public Relations. Knowing which products work for which conditions and how to safely administer them to maximize results are key in leading a successful regenerative medicine practice.
With the Cellular Therapy course and others offered by the ISSCA, physicians will learn these valuable protocols and more about product offerings and how to choose the most effective ones. The Cellular Therapy course will prepare physicians with the necessary theoretical and practical knowledge needed to effectively and safely secure better patient outcomes when using cellular therapies. With this training, physicians will gain knowledge from leading scientists in the field, learn valuable information on safety standards and quality control from top manufacturers, be positioned to perform these procedures and open a Stem Cell Center practice, join the ISSCA’s network, and enjoy the benefits of an exponentially growing industry worldwide.
Practitioners enrolling in the online course will gain access to online lectures from some of the leading names in the field of regenerative medicine spanning a number of topics critical to understanding the foundations of cellular therapy. In addition to online lectures, enrollees gain access to important supporting documents; The Condition Book, outlining stem cells treatment protocols for seven common conditions; and valuable case studies, all designed to deliver the knowledge needed to successfully implement stem cells treatments in a clinical setting.
And physicians looking to enroll in this course and other offerings by the ISSCA are in good hands. The group is widely considered as the global standard bearer when it comes to education and research in the regenerative medicine field. For years, the ISSCA has played a critical role in bridging the gap between the science behind stem cells and regenerative medicine and the practical application of that science in a clinical setting.
“We are pleased to add the online Cellular Therapy course to our growing number of course offerings designed to deliver the skills and education needed to practitioners eager to implement stem cells treatment protocols into their existing practices,” said Novas. “The course gives physicians the skills needed to utilize these highly effective treatments to help patients suffering from degenerative diseases while expanding on the ISSCA’s mission to continue to serve as the premier educational resource for physicians across the globe looking to introduce stem cells treatments into their practices.”
To learn more about the ISSCA, visit www.issca.us. To learn more about the group’s new online Cellular Therapy course or to register, visit https://www.cellulartherapycourse.com/
Miami Lakes Award Program Honors the Achievement
MIAMI LAKES November 14, 2019 — Global Stem Cells Group has been selected for the 2019 Best of Miami Lakes Award in the Biotechnology Company category by the Miami Lakes Award Program.
Each year, the Miami Lakes Award Program identifies companies that we believe have achieved exceptional marketing success in their local community and business category. These are local companies that enhance the positive image of small business through service to their customers and our community. These exceptional companies help make the Miami Lakes area a great place to live, work and play.
Various sources of information were gathered and analyzed to choose the winners in each category. The 2019 Miami Lakes Award Program focuses on quality, not quantity. Winners are determined based on the information gathered both internally by the Miami Lakes Award Program and data provided by third parties.
About Miami Lakes Award Program
The Miami Lakes Award Program is an annual awards program honoring the achievements and accomplishments of local businesses throughout the Miami Lakes area. Recognition is given to those companies that have shown the ability to use their best practices and implemented programs to generate competitive advantages and long-term value.
The Miami Lakes Award Program was established to recognize the best of local businesses in our community. Our organization works exclusively with local business owners, trade groups, professional associations and other business advertising and marketing groups. Our mission is to recognize the small business community’s contributions to the U.S. economy.
SOURCE: Miami Lakes Award Program
Miami Lakes Award Program
The awards recognize the physicians’ leadership in education and instruction in regenerative medicine
MIAMI LAKES, Florida—Three faculty members with the International Society for Stem Cell Application (ISSCA) were honored with awards at the organization’s recent regenerative medicine conference held at the University of Miami on October 24-27. The awards were sponsored by the Sociedad Internacional en Investigación, Salud, Desarrollo Empresarial y Tecnologías (SISSDET) and lauded the honorees for their commitment to leadership and education in the field of regenerative medicine.
The three recipients of the awards are Dr. Damian Ariel Siano, Dra. Maritza Novas, and Dra. Silvina Pastrana. All three have continued to partner with the ISSCA and have notable contributions to the field by offering courses in regenerative medicine, helping thousands of doctors around the world add stem cells therapies to their medical practices.
Dr. Damian Ariel Siano is an orthopedic physician from Argentina who has dedicated his professional life to treat sports injuries. He is one of the most renowned sports medicine specialists in South America. Dr. Siano currently works with one of the most famous soccer teams in Argentina, using cell therapies to help professional athletes avoid unnecessary surgery and recuperate quicker from injuries.
Dra. Maritza Novas currently serves as the Director of Research and Development for the Global Stem Cells Group. For the past 10 years, she has dedicated herself to educating doctors in the latest stem cells advancements and conducting stem cell research. Dra. Novas has visited all continents, sharing her knowledge as a stem cells practitioner and researcher.
Dra. Silvina Pastrana is one of the first doctors that helped form the ISSCA. She has become a visionary in the field and is noted for creating her own stem cells protocols and using complementary therapies to get better results in patient who utilize cell therapies. Dra. Pastrana combines both ozone and vitamin C therapies before employing stem cell protocols, obtaining excellent results in treating patients with arthritis.
“The ISSCA is committed to helping physicians who want to add regenerative medicine to their practices gain the education and tools to do that,” said Benito Novas, Vice President of Public Relations for ISSCA. “The three doctors recognized at our recent event at the University of Miami are prime examples of the high-quality instructors that physicians can anticipate working with when then attend one of our conferences. Congratulations to our faculty on receiving this prestigious award, and thank you to SISSDET for recognizing their accomplishments.”
ISSCA is a global leader in stem cells research, applications, and education, partnering with major global institutions and locations worldwide to host its independent medical congresses. To learn more about the ISSCA and its all of its past and upcoming events, visit http://www.issca.us
The organization seeks to improve education and access to stem cells therapies for physicians and patients worldwideThe organization seeks to improve education and access to stem cells therapies for physicians and patients worldwide
MIAMI LAKES, Florida—Following two recent highly successful conferences, the International Society for Stem Cell Application (ISSCA) is set to offer six additional events on its training calendar to round out 2019. Recent events attracting physicians across the globe include a conference held at the University of Miami and the ISSCA’s 6th Annual Regenerative Medicine Symposium in Buenos Aires. With its upcoming slate of events, the group is hoping to receive the same positive response.
One of the ISSCA’s missions is to share the latest in stem cells protocols and clinical applications with physicians across the globe, so they can implement stem cells therapies into their practices. By adding these protocols to their practices, physicians can help alleviate suffering and improve recuperation times for patients diagnosed with a host of degenerative diseases and injuries.
To accomplish its mission, the ISSCA will host the following events in 2019:
- Uccle, Belgium – November 15-16
- Mexico City – November 22-23
- Cochabamba, Bolivia – November 22-23
- Miami, FL – November 29-30
- Buenos Aires, Argentina – December 6-7
- Bogota, Colombia – December 13-14
“We invite all physicians interested in adding stem cells therapies to their practices to join us at one of our upcoming conferences,” said Benito Novas, Vice President of Public Relations for ISSCA. “Attendees will learn from highly trained physicians and researchers in the field of regenerative medicine and take away the necessary education and tools to implement the latest stem cells therapies into their own practices.”
The ISSCA is a global leader in stem cells research, applications, and education, partnering with major global institutions and locations worldwide to host its independent medical congresses. To learn more about the ISSCA and its all of its past and upcoming events, visit http://www.issca.us